Regulus Therapeutics Inc. (NASDAQ:RGLS) released topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen (RGLS8429) autosomal dominant polycystic kidney disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results